Skip to main content

Life Sciences is now live. See how →

Patent Examiner Pancham Bakshi

Art Unit 1623 · Carbohydrates, Medicinal Chemistry & Bio-Affecting Compositions · Tech Center 1600 · 393 applications filed 2021–2026

⚑ Hard · harder than 76% of examiners● Free examiner data

Pancham Bakshi is a USPTO patent examiner in Art Unit 1623 (Carbohydrates, Medicinal Chemistry & Bio-Affecting Compositions) with 393 applications from filing years 2021–2026. Examiner Bakshi's allowance rate is 68.0%, below the 81.9% USPTO average for applications filed in the same years. The examiner ranks harder than 76% of examiners. In 2021, decided applications with an examiner interview were allowed 34.7 percentage points more often than those without.

Draft a response to Examiner BakshiSee the strategy data ↓

Data through October 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Hard
harder than 76% of examiners
Easier76th percentileHarder
Allowance rate vs peers
Examiner Bakshi68.0%
Art Unit 162363.9%
USPTO average81.9%
Allowance rate
68.0%
▼ USPTO avg 81.9%
Applications
393
filing years 2021–2026
First-action allowance
10.4%
patented with no rejection
Abandoned
21.1%
share of applications
Avg office actions
1.3
USPTO avg 1.4
Days to first OA
700
▲ USPTO 627
RCE rate
20.9%
USPTO 20.3%
Interview rate
27.7%
USPTO 28.2%

Examiner details

  • Art unit1623 · Carbohydrates, Medicinal Chemistry & Bio-Affecting Compositions
  • Title / gradePrimary Patent Examiner · GS-14
  • Service15 years
  • Phone(571) 270-3463
  • Email[email protected]
  • LocationAlexandria, VA 22314
  • In USPTO recordsBAKSHI, PANCHAM
Full signatory authority

Examiner Bakshi can allow an application without a supervisory sign-off.

Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions556 · Organic Compounds (Class 532-570 Series)536 · Organic Compounds: Carbohydrates (Class 532-570 Series)

How to improve your odds with Examiner Bakshi

  • The data favors an interview. Interviewed cases were allowed more often in all 3 measured years, by 29.8 to 34.7 points.
  • Plan for the timeline. First office action averages 700 days vs the 627-day USPTO norm.
  • Expect a §103. Obviousness is the most-issued rejection (188), and applicants overcame it 54.7% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in all 3 measured years, by 5.3 to 33.8 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§102 Novelty165 issued · 53.3% overcome
§103 Obviousness188 issued · 54.7% overcome
§112 Definiteness & disclosure186 issued · 63.4% overcome
How applicants traverse §103 rejections🔒 Members

Of the 47 winning responses to Examiner Bakshi's §103 rejections that Boundly has classified, 31 (66%) amended the claims and argued, 9 argued without amending, and 7 amended without arguing. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §103 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Bakshi?

Draft your response with Examiner Bakshi's record and Art Unit 1623's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response tools in AI Studio.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Bakshi.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202323.0%77.8%72.5%+5.3pp
202215.8%100.0%66.2%+33.8pp
202126.2%76.9%61.1%+15.8pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/593053Reactive Secondary Boranes and Methods for Synthesis ThereofPatented0🔒 View
18/017524Process for Synthesis of Organosilicon Compounds from HalosilanesPatented2🔒 View
18/265554Method for Preparing Acrylic AcidPatented1🔒 View
18/194805Gold Nonoclusters, Dopamine Biosensors Including Them, and Methods for Diagnosing Neurological Diseases Using the SamePatented1🔒 View
See all 393 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1623 technology

Carbohydrate chemistryMedicinal chemistryBio-affecting compositionsOrganic synthesisTop CPC C07D · A61K · C07H
About this examiner. Pancham Bakshi examines in Art Unit 1623 (Carbohydrates, Medicinal Chemistry & Bio-Affecting Compositions, Tech Center 1600). The art unit's docket includes carbohydrate chemistry, medicinal chemistry, bio-affecting compositions, and organic synthesis. Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Pancham Bakshi's allowance rate?
Examiner Bakshi's allowance rate is 68.0%, compared with 81.9% across the USPTO and 63.9% in Art Unit 1623 for applications filed in the same years. That rate ranks Examiner Bakshi harder than 76% of examiners.
Is Examiner Bakshi a hard examiner?
Somewhat. Examiner Bakshi ranks harder than 76% of examiners, in the 76th difficulty percentile (hard). Examiner Bakshi has a 68.0% allowance rate versus 81.9% across the USPTO and 63.9% in Art Unit 1623, 1.3 office actions per application versus 1.4, and an RCE rate of 20.9% versus 20.3% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Bakshi?
In this examiner's record, yes. Decided applications with an interview were allowed more often in each of the 3 measured years, by 29.8 to 34.7 percentage points. In 2021, 90.3% of decided applications with an interview were allowed, versus 55.6% of those without.
What is Examiner Bakshi's most common rejection?
§103 obviousness, issued 188 times in the data. Applicants overcame it 54.7% of the time. Of the 47 winning responses Boundly has classified, 31 amended the claims and argued.
Is an RCE worth filing with Examiner Bakshi?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in each of the 3 measured years, by 5.3 to 33.8 percentage points. In 2021, 76.9% of decided applications with an RCE were allowed, versus 61.1% of those without one.
How long until the first office action from Examiner Bakshi?
About 700 days on average, versus 627 days across the USPTO for applications filed in the same years.
How do I contact Examiner Pancham Bakshi?
Examiner Bakshi can be reached by phone at (571) 270-3463 or by email at [email protected]. The examiner's direct line is also listed at the end of the examiner's office actions.

Put Examiner Bakshi's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Pancham Bakshi, or see an error? Request a correction.